SEATTLE, July 28, 2014 /PRNewswire/ -- CTI BioPharma Corp.
(CTI) (NASDAQ and MTA: CTIC) announced today that it will report
its second quarter 2014 financial results on Monday, August 4, 2014, after the close of the
U.S. financial markets. Following the announcement, members of the
management team will host a webcast conference call to discuss the
results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m.
PDT). Access to the event can be obtained as follows:
Monday, August 4
1:30 p.m. PDT/4:30 p.m. EDT/10:30 p.m.
CEST
1-888-461- 2024 (domestic)
+1 719-325-2464 (international)
To access the live audio webcast or the subsequent archived
recording, visit CTI's website, www.ctibiopharma.com. Webcast and
telephone replays of the conference call will be available at
approximately two hours after completion of the call. Callers can
access the replay by dialing 1-888-203-1112 (domestic) or +1
719-457-0820 (international). The access code for the replay is
#1937280. The telephone replay will be available until Monday,
August 11, 2014.
About CTI BioPharma
CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a
biopharmaceutical company focused on the acquisition, development
and commercialization of novel targeted therapies covering a
spectrum of blood-related cancers that offer a unique benefit to
patients and healthcare providers. CTI has a commercial presence in
Europe and a late-stage
development pipeline, including pacritinib, CTI's lead product
candidate that is currently being studied in a Phase 3 program for
the treatment of patients with myelofibrosis. CTI is headquartered
in Seattle, Washington, with
offices in London and Milan under
the name CTI Life Sciences Limited. For additional information and
to sign up for email alerts and get RSS feeds, please visit
www.ctibiopharma.com.
Contacts:
Monique
Greer
+1 206-272-4343
mgreer@ctibiopharma.com
Ed Bell
+1 206-282-7100
ebell@ctibiopharma.com
In Europe: CTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 94751572
lvilla@cti-lifesciences.com
SOURCE CTI BioPharma Corp.